公开(公告)号：US10806781B2

公开(公告)日：2020-10-20

申请号：US16159221

申请日：2018-10-12

申请人： Takeda Vaccines, Inc.

发明人： Dan T. Stinchcomb ,  Jill A. Livengood ,  Laszlo Varga

IPC分类号： C12N7/00 ,  A61K39/12 ,  A61K47/22 ,  A61K47/26 ,  A61K47/42 ,  A61K39/00

摘要： Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.

公开(公告)号：US10137186B2

公开(公告)日：2018-11-27

申请号：US14209921

申请日：2014-03-13

申请人： TAKEDA VACCINES, INC.

发明人： Dan T. Stinchcomb ,  Jill A. Livengood ,  Laszlo Varga

IPC分类号： C12N7/00 ,  A61K39/12 ,  A61K47/22 ,  A61K47/26 ,  A61K47/42 ,  A61K39/00

摘要： Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.

公开(公告)号：US20190134182A1

公开(公告)日：2019-05-09

申请号：US16159221

申请日：2018-10-12

申请人： Takeda Vaccines, Inc.

发明人： Dan T. Stinchcomb ,  Jill A. Livengood ,  Laszlo Varga

IPC分类号： A61K39/12 ,  A61K47/42 ,  A61K47/26 ,  A61K47/22

摘要： Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.